Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04167618
Recruitment Status : Recruiting
First Posted : November 19, 2019
Last Update Posted : November 24, 2021
Information provided by (Responsible Party):
Y-mAbs Therapeutics

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 15, 2024
Estimated Study Completion Date : December 15, 2024